Literature DB >> 19082473

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Ralf Hildenbrand1, Antonela Schaaf.   

Abstract

The urokinase-system has been implicated in tumor spread. The serine protease urokinase-type plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1) are involved in the control of extracellular turnover, cell migration, invasion, cell signalling, proliferation, apoptosis and angiogenesis leading to a variety of different responses, under both physiological and pathological conditions. uPA and PAI-1 were the first novel tumor biological factors to be validated at the highest level of evidence regarding their clinical utility in breast cancer. However, it is unclear whether it is their (relative) levels in the tumor stroma or in the tumor cells themselves that is the most relevant to patients outcome. This is the first study in which tumor cells and stromal tissue of invasive breast carcinomas were separated by laser capture microdissection followed by ELISA-based determination of the uPA, uPAR and PAI-1 levels. In addition, we localized uPA, uPAR and PAI-1 distribution in invasive breast cancer (n=30) and in ductal carcinoma in situ (DCIS, n=30) by immunohistochemistry and in situ hybridization. We have demonstrated that no significant differences between uPA, uPAR and PAI-1 levels in tumor stroma only, tumor cells only and not separated breast cancer tissue exist (p>0.05). Our results suggest that similar expression levels of these factors in both compartments and in not separated breast cancer tissue may have the same impact on the clinical behavior of breast cancer. These results are an important issue for practical use of tissue sampling. For using uPA and PAI-1 levels as prognostic and predictive factors in breast cancer the quantity of tumor stroma in the tumor tissue specimen is not relevant for assessment patients outcome. Our results were confirmed by immunohistochemistry and in situ hybridization analysis showing that in nearly all cases of invasive carcinomas and DCIS fibroblasts as well as macrophages strongly express uPA, uPAR and PAI-1. Prompted by our immunohistological results that nearly all myoepithelial cells of DCIS exhibit uPA, uPAR and PAI-1, we investigated these important host cells in detail. We have demonstrated by multimodal methods that uPAR and PAI-1 protein and mRNA is expressed in most myoepithelial cells of DCIS. Additionally, we furnish evidence that uPAR expression of myoepithelial cells are important for uPAR Vitronectin-associated cell-matrix interaction, which regulates cell adhesion and detachment. We speculate that the loss of the anti-invasive myoepithelial cell layer in DCIS may be triggered by PAI-1 and could be an early sign of subsequent tumor cell invasion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19082473

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  28 in total

1.  An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.

Authors:  Shafaat A Rabbani; Bushra Ateeq; Ani Arakelian; Maria Luisa Valentino; David E Shaw; Lisa M Dauffenbach; Christopher A Kerfoot; Andrew P Mazar
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.

Authors:  Anne Masset; Catherine Maillard; Nor Eddine Sounni; Nathalie Jacobs; Françoise Bruyére; Philippe Delvenne; Marlene Tacke; Thomas Reinheckel; Jean-Michel Foidart; Lisa M Coussens; Agnès Noël
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

3.  Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.

Authors:  Sujoy Dutta; Chirosree Bandyopadhyay; Virginie Bottero; Mohanan V Veettil; Lydia Wilson; Michael R Pins; Karen E Johnson; Case Warshall; Bala Chandran
Journal:  Mol Oncol       Date:  2014-01-04       Impact factor: 6.603

Review 4.  Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells.

Authors:  Amy L Strong; Matthew E Burow; Jeffrey M Gimble; Bruce A Bunnell
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

5.  Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer.

Authors:  Christina Vorvis; Maria Hatziapostolou; Swapna Mahurkar-Joshi; Marina Koutsioumpa; Jennifer Williams; Timothy R Donahue; George A Poultsides; Guido Eibl; Dimitrios Iliopoulos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-05-05       Impact factor: 4.052

6.  Stromal cells of endometrial carcinoma promotes proliferation of epithelial cells through the HGF/c-Met/Akt signaling pathway.

Authors:  Min Li; Xiaoyan Xin; Tingting Wu; Teng Hua; Hongbin Wang; Hongbo Wang
Journal:  Tumour Biol       Date:  2015-03-18

7.  Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.

Authors:  Yuqi Jing; Valery Chavez; Yuguang Ban; Nicolas Acquavella; Doraya El-Ashry; Alexey Pronin; Xi Chen; Jaime R Merchan
Journal:  Mol Cancer Res       Date:  2017-07-05       Impact factor: 5.852

8.  Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.

Authors:  Jiexian Jing; Shumin Zheng; Cunzhi Han; Lili Du; Yongfeng Guo; Pei Wang
Journal:  J Clin Lab Anal       Date:  2012-01       Impact factor: 2.352

9.  Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.

Authors:  Fan Zeng; Guanzhang Li; Tao Jiang; Ying Zhang; Xiu Liu; Kenan Zhang; Hua Huang
Journal:  Oncologist       Date:  2021-03-28

10.  In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.

Authors:  Yuqi Jing; Valery Chavez; Natasha Khatwani; Yuguang Ban; Andrea P Espejo; Xi Chen; Jaime R Merchan
Journal:  Cancer Gene Ther       Date:  2020-03-31       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.